Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538524 | 0.84 | CYP19A1 (0.76) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL28010816 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL28035668 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL27882415 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL11759023 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL11131614 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL4205339 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL8365863 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL28795788 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 | |
| SCHEMBL28071098 | 0.82 | CYP19A1 (0.73) | KMT2AHPGDCYP19A1L3MBTL1ASAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493905-B1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT CO LLC (PR) | 2016-11-30 | — | — | EP | disclosed |
| US-8822435-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8710215-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2154123-B1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2013-02-07 | — | — | US | disclosed |
| US-8314081-B2 | Bisphosphonate compounds | WARNER CHILCOTT COMPANY, LLC (US) | 2012-11-20 | — | — | US | disclosed |
| US-8309753-B2 | Method for producing optically active cyanohydrin compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| EP-2493905-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | Warner Chilcott Company, LLC (PR) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056589-A1 | BISPHOSPHONATE COMPOUNDS FOR TREATING BONE METABOLISM DISORDERS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | WARNER CHILCOTT COMPANY, LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264005-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-7851659-B2 | Method for producing benzaldehyde compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20100234645-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2154123-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194389-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | KMT2A 4240/4885HPGD 358/4885CYP19A1 630/4885 |
| US-20110098251-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | KMT2A 4240/4885HPGD 358/4885CYP19A1 630/4885 |
| US-20100234645-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | NQO1, NQO2, NDUFC2 | KMT2A 548/4885HPGD 564/4885CYP19A1 786/4885 |
| US-20130035482-A1 | BISPHOSPHONATE COMPOUNDS | BPGM, PPIP5K2, PTEN | KMT2A 4240/4885HPGD 358/4885CYP19A1 630/4885 |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | CBR3, ACSL3, CCNL2 | KMT2A 1113/4885HPGD 1408/4885CYP19A1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.